| __timestamp | Eli Lilly and Company | Teva Pharmaceutical Industries Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 6620800000 | 5078000000 |
| Thursday, January 1, 2015 | 6533000000 | 4717000000 |
| Friday, January 1, 2016 | 6452000000 | 5096000000 |
| Sunday, January 1, 2017 | 6588100000 | 4986000000 |
| Monday, January 1, 2018 | 5975100000 | 4214000000 |
| Tuesday, January 1, 2019 | 6213800000 | 3806000000 |
| Wednesday, January 1, 2020 | 6121200000 | 3671000000 |
| Friday, January 1, 2021 | 6431600000 | 3528000000 |
| Saturday, January 1, 2022 | 6440400000 | 3445000000 |
| Sunday, January 1, 2023 | 6941200000 | 3498000000 |
| Monday, January 1, 2024 | 8593800000 | 3702000000 |
Infusing magic into the data realm
In the ever-evolving pharmaceutical industry, understanding spending patterns is crucial for strategic planning. Over the past decade, Eli Lilly and Company and Teva Pharmaceutical Industries Limited have demonstrated contrasting trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Eli Lilly's SG&A expenses have shown a steady increase, peaking in 2023 with a 5% rise from the previous year. In contrast, Teva's SG&A expenses have decreased by approximately 31% over the same period, reflecting a strategic shift towards cost efficiency.
This divergence highlights the different strategic priorities of these pharmaceutical giants. While Eli Lilly invests heavily in administrative and sales functions, Teva focuses on streamlining operations. These insights provide a window into the financial strategies that shape the competitive landscape of the pharmaceutical sector.
Comparing SG&A Expenses: Eli Lilly and Company vs Neurocrine Biosciences, Inc. Trends and Insights
Selling, General, and Administrative Costs: Eli Lilly and Company vs Verona Pharma plc
Comparing SG&A Expenses: Eli Lilly and Company vs CRISPR Therapeutics AG Trends and Insights
Eli Lilly and Company vs Amicus Therapeutics, Inc.: SG&A Expense Trends
Selling, General, and Administrative Costs: Eli Lilly and Company vs MorphoSys AG
Eli Lilly and Company vs Supernus Pharmaceuticals, Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Amgen Inc. and Teva Pharmaceutical Industries Limited
Breaking Down SG&A Expenses: argenx SE vs Teva Pharmaceutical Industries Limited
Comparing SG&A Expenses: Teva Pharmaceutical Industries Limited vs Ultragenyx Pharmaceutical Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for Teva Pharmaceutical Industries Limited and CRISPR Therapeutics AG
Teva Pharmaceutical Industries Limited vs Arrowhead Pharmaceuticals, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Teva Pharmaceutical Industries Limited or Supernus Pharmaceuticals, Inc.